uploads/2018/07/lab-217041_1280.jpg

How Analysts Are Rating Puma Biotechnology in July

By

Updated

Stock performance

On July 5, Puma Biotechnology (PBYI) stock closed at $58.75, which represents a 25% growth from its 52-week low of $47 on June 7.

On June 26, the stock rose 24.36% to $63.55 from its previous day’s close of $51.10. The rise was due to the company’s announcement that the European Medicines Agency’s Committee for Medicinal Products for Human Use (or CHMP) recommended a positive opinion for the approval of the MAA (Marketing Authorization Application) for neratinib as an extended adjuvant treatment in individuals with early-stage HER2[1. human epidermal growth factor receptor 2]-positive hormone receptor-positive breast cancer.

The positive recommendation from CHMP comes after a reexamination of negative recommendations at the meeting for the MAA on February 23.

Article continues below advertisement

Analysts’ recommendations

Of the six analysts tracking Puma Biotechnology in July, two of them have recommended a “strong buy,” and one has recommended a “buy.” Three analysts have recommended a “hold.”

On July 5, the company had a consensus 12-month target price of $94.17, which represents a 60.29% return on investment over the next 12 months.

Peer ratings

Of the 18 analysts tracking Incyte (INCY) in July, 78% have recommended a “buy” for the stock. On July 5, Incyte had a consensus 12-month target price of $83.71, which represents an 18.65% return on investment over the next 12 months.

Of the 13 analysts tracking Seattle Genetics (SGEN) in July, 62% of them have recommended a “buy.” On July 5, Seattle Genetics had a consensus 12-month target price of $68.91, which represents a 0.55% return on investment over the next 12 months.

Of the 16 analysts tracking Alnylam Pharmaceuticals (ALNY) in July, 75% of them have recommended a “buy.” On July 5, Alnylam Pharmaceuticals had a consensus 12-month target price of $146.81, which represents a 49.73% return on investment over the next 12 months.

Advertisement

More From Market Realist